There are no conflicts of interest related to this manuscript. Dr. Laffin has been a consultant and/or served on steering committees for AstraZeneca, Crispr Therapeutics, Eli Lilly, Idorsia, Kardigan, Medtronic, Mineralys Therapeutics, Novo Nordisk, Recor, Ripple Medical, and Stability Health; has received research funding from AstraZeneca. The other authors have no disclosures.